Unexplained infertility Medical Services in China

Unexplained infertility is a clinical diagnosis assigned to couples who have failed to achieve pregnancy after at least 12 months of regular, unprotected intercourse—and for whom comprehensive fertility evaluation reveals no identifiable cause. This diagnosis applies only after thorough assessment of both partners, including semen analysis, ovarian reserve testing (AMH, AFC, FSH), ovulation confirmation, hysterosalpingography or sonohysterography to evaluate tubal patency and uterine anatomy, and endometrial assessment where indicated. Despite advances in reproductive medicine, approximately 10–30% of infertile couples worldwide receive this diagnosis—making it one of the most common indications for assisted reproductive technology (ART) in specialized reproductive medicine departments. The pathogenesis remains elusive but is thought to involve subtle, multifactorial disruptions: subclinical oocyte or sperm dysfunction (e.g., impaired chromatin integrity, mitochondrial inefficiency, or epigenetic dysregulation), minor endometrial receptivity defects not detectable by standard histology or imaging, undiagnosed immunologic factors (e.g., natural killer cell dysregulation or anti-endometrial antibodies), or transient hormonal imbalances affecting embryo-endometrium synchrony. Emerging evidence also implicates oxidative stress, microbiome dysbiosis in the upper genital tract, and genetic polymorphisms influencing folliculogenesis or implantation pathways. Epidemiologically, unexplained infertility affects roughly 1 in 15 couples of reproductive age globally, with prevalence rising in high-income countries due to delayed childbearing and increased diagnostic scrutiny. Risk factors include advanced maternal age (≥35 years), mild obesity (BMI 25–30), chronic low-grade inflammation, psychological stress, environmental toxin exposure (e.g., phthalates, BPA), and lifestyle factors such as smoking, excessive caffeine intake, or sedentary behavior—though none are causative alone. Importantly, male factors contribute significantly in up to 40% of cases previously labeled 'unexplained', underscoring the need for advanced sperm function testing (e.g., DNA fragmentation assay). The psychosocial burden is profound: patients frequently report elevated anxiety, depression, marital strain, diminished sexual intimacy, and feelings of inadequacy or stigma—particularly in cultures where fertility is tightly linked to identity and social standing. Quality of life metrics consistently show lower scores in domains of emotional well-being, social functioning, and vitality compared to fertile peers or even those with diagnosed infertility causes. Without intervention, spontaneous conception rates remain modest—approximately 15–25% over two years—but prognosis improves markedly with evidence-based management, including expectant monitoring with timed intercourse, ovulation induction with clomiphene or letrozole, intrauterine insemination (IUI), or in vitro fertilization (IVF), which offers the highest per-cycle success rate (40–55% live birth rate per cycle in women under 35). Early referral to reproductive endocrinology and infertility (REI) specialists ensures timely escalation and personalized care aligned with patient values, timelines, and financial considerations.

Unexplained infertility (UI) is diagnosed when a heterosexual couple fails to achieve pregnancy after 12 months of regular, unprotected intercourse—and comprehensive evaluation reveals no identifiable cause: ovulation is confirmed, semen analysis falls within WHO reference limits, tubal patency is verified via hysterosalpingography or laparoscopy, and uterine anatomy is normal. UI accounts for approximately 10–30% of all infertility cases and represents a heterogeneous clinical entity likely involving subtle molecular, endometrial, embryonic, immunologic, or epigenetic factors not yet detectable with current diagnostic tools. Management is individualized, evidence-based, and staged—progressing from conservative interventions to assisted reproductive technologies (ART) as appropriate.

Conservative treatment forms the initial cornerstone. Lifestyle optimization is strongly recommended: patients are counseled on maintaining a BMI between 18.5–24.9 kg/m², cessation of tobacco and excessive alcohol use, moderation of caffeine intake (<200 mg/day), and avoidance of environmental endocrine disruptors (e.g., BPA, phthalates). Regular moderate exercise (150 minutes/week of aerobic activity) improves insulin sensitivity and ovarian function. Timed intercourse—guided by urinary luteinizing hormone (LH) surge detection or basal body temperature charting—is advised for at least 3–6 cycles. While empirical data on its efficacy in UI is modest, it carries zero risk, minimal cost, and preserves natural conception physiology. Psychological support—including cognitive behavioral therapy (CBT) or fertility-specific counseling—is integral, given the well-documented association between chronic stress, hypothalamic-pituitary-ovarian axis dysregulation, and reduced conception probability.

Pharmacologic intervention typically begins with ovulation enhancement. Clomiphene citrate (50–100 mg/day, days 3–7) remains first-line due to its oral administration, low cost, and favorable safety profile; however, its anti-estrogenic effects on cervical mucus and endometrium may limit efficacy in UI. Letrozole (2.5–7.5 mg/day, days 3–7), an aromatase inhibitor, is increasingly preferred as first-line in many centers: it induces mono-follicular development with superior endometrial thickness and pregnancy rates compared to clomiphene in randomized trials. Gonadotropins (e.g., recombinant FSH) are reserved for letrozole/clomiphene non-responders or those pursuing intrauterine insemination (IUI); they require rigorous ultrasound and estradiol monitoring to mitigate ovarian hyperstimulation syndrome (OHSS) and multiple gestation risks. Adjuvant therapies remain investigational: low-dose aspirin (81 mg/day) lacks robust evidence in UI; while some meta-analyses suggest marginal benefit in women with elevated natural killer (NK) cell activity, routine immunomodulation (e.g., intravenous immunoglobulin, corticosteroids) is not supported by high-quality RCTs and is discouraged outside research protocols. Metformin is indicated only if insulin resistance or PCOS features coexist—not empirically in normoglycemic UI.

Surgical management has a limited but defined role. Laparoscopy is not routinely indicated for UI diagnosis alone but may be considered if clinical suspicion arises for subtle endometriosis (e.g., chronic pelvic pain, dyspareunia), adhesions, or occult tubal pathology missed on HSG. Excision of stage I–II endometriosis or lysis of filmy adhesions may improve spontaneous conception rates by up to 30–40% over expectant management at 12 months. Hysteroscopic resection of submucosal fibroids (>1 cm), endometrial polyps, or intrauterine synechiae—identified on saline infusion sonohysterography (SIS) or hysteroscopy—is strongly recommended prior to ART, as these lesions impair embryo implantation. However, routine hysteroscopy in asymptomatic UI patients without imaging abnormalities is not evidence-based and may introduce iatrogenic injury.

China offers distinct advantages in UI management. The country hosts one of the world’s most advanced and accessible ART infrastructures, with over 600 certified IVF centers—including pioneering institutions like Peking University Third Hospital and Shanghai Jiao Tong University Affiliated International Peace Maternity and Child Health Hospital—operating under stringent National Health Commission (NHC) regulatory oversight. Chinese clinicians demonstrate exceptional expertise in mild ovarian stimulation protocols (e.g., modified natural cycle IVF, progestin-primed ovarian stimulation [PPOS]), which reduce OHSS risk and improve patient tolerability without compromising live birth rates. Integration of traditional Chinese medicine (TCM) is uniquely standardized: acupuncture administered per protocol (e.g., ST29, SP6, CV4 bilaterally) alongside IVF cycles shows consistent improvement in endometrial receptivity and clinical pregnancy rates in multicenter RCTs published in journals such as *Fertility and Sterility*. Moreover, China’s national health insurance now covers up to 80% of diagnostic testing and certain ART procedures (e.g., IUI, first IVF cycle) in select provinces—a policy unmatched in most high-income countries. Shorter wait times (often <3 months for IVF initiation vs. >12 months in parts of Europe) and multidisciplinary care teams—including reproductive endocrinologists, embryologists, TCM physicians, nutritionists, and mental health specialists—enhance continuity and outcomes.

Recovery and long-term follow-up emphasize holistic resilience. Patients undergoing pharmacologic or surgical interventions should undergo post-procedure assessment of ovarian reserve (AMH, AFC), endometrial thickness (>7 mm pre-ovulation), and luteal phase adequacy (mid-luteal progesterone >10 ng/mL). After failed cycles, psychological debriefing and shared decision-making regarding next steps—whether continuing with optimized IUI, transitioning to IVF, or considering donor gametes—are essential. Nutritional guidance focuses on Mediterranean-style diets rich in omega-3 fatty acids, antioxidants (vitamin C, E, selenium), and folate (800 mcg/day). Sleep hygiene (7–9 hours/night, consistent circadian rhythm) supports gonadotropin pulsatility. For couples proceeding to IVF, blastocyst culture with preimplantation genetic testing for aneuploidy (PGT-A) may be considered in recurrent implantation failure, though its universal utility in UI remains debated. Finally, all patients should receive age-appropriate fertility preservation counseling: women >35 years with UI warrant expedited ART referral, as cumulative live birth rates decline significantly beyond age 37—even with otherwise unremarkable diagnostics.